2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies

Powder Micromeritics and Granulation Technologies

Solid dosage forms represent over $70%$ of all pharmaceutical prescriptions dispensed in Canada. The manufacture of uniform, robust tablets and capsules depends directly on the science of small particles (micromeritics) and powder flow dynamics.

Characterization of Powder Flow and Compressibility

1. Angle of Repose ($\theta$): The maximum angle possible between the surface of a powder pile and the horizontal plane ($\tan\theta = \frac{h}{r}$).
   • $\theta < 25^\circ$: Excellent flow
   • $\theta = 25^\circ\text{ to }30^\circ$: Good flow
   • $\theta = 30^\circ\text{ to }40^\circ$: Fair flow (passable)
   • $\theta > 40^\circ$: Poor flow / cohesive powder
2. Carr's Compressibility Index ($C$): $C = \left(\frac{\rho_{\text{tapped}} - \rho_{\text{bulk}}}{\rho_{\text{tapped}}}\right) \times 100\%$
   • $C < 10%$: Excellent flowability
   • $C = 11%\text{ to }15%$: Good flowability
   • $C > 25%$: Poor flowability (requires granulation or glidants)
3. Hausner Ratio ($H$): $H = \frac{\rho_{\text{tapped}}}{\rho_{\text{bulk}}}$
   • $H < 1.25$: Indicates free-flowing powder
   • $H > 1.35$: Indicates highly cohesive powder prone to arching and rat-holing in tablet press hoppers.

Granulation Methods

• Direct Compression: Powder blend containing API and directly compressible excipients is compressed without prior granulation. It is the simplest and most cost-effective method, ideal for heat- and moisture-sensitive drugs, but requires excellent powder flow and compressibility (e.g., using spray-dried lactose or microcrystalline cellulose).
• Dry Granulation (Roller Compaction / Slugging): Powders are compacted under high mechanical pressure into ribbons or large slugs, then milled into uniform granules. This method avoids all water and heat, making it suitable for moisture-sensitive APIs (e.g., aspirin, effervescent salts).
• Wet Granulation: Powder blend is mixed with a liquid binder solution to form a wet mass, passed through screens, dried, and sized. It ensures superior content uniformity for low-dose drugs and improves flowability, but involves moisture and thermal exposure.

---

Tablet Excipients and Formulation Science

Tablet formulations consist of active ingredients intimately blended with functional excipients, each serving a vital role in processing, stability, or drug release.

---

Tablet Manufacturing Defects and Quality Standards

During high-speed rotary tableting, improper formulation or machine settings cause characteristic manufacturing defects:

• Capping: Partial or complete separation of the top or bottom crown of a tablet from the main body, caused by air entrapment, excessive fine particles, or high compression speeds.
• Lamination: Separation of a tablet into two or more distinct horizontal layers, caused by air entrapment during pre-compression or relaxation of elastic materials.
• Sticking and Picking: Granulation adhering to the die wall (sticking) or punch faces, resulting in missing fragments from the tablet face or embossed lettering (picking); caused by excessive moisture or inadequate lubrication.
• Mottling: Unequal, non-uniform distribution of color across the tablet surface, caused by migration of soluble dyes during wet granule drying.
• Friability Testing (USP Standard): Tablets are rotated in a drum (Roche friabilator) for 100 revolutions (25 rpm for 4 minutes). The maximum acceptable weight loss for uncoated commercial tablets is $< 1.0%$, ensuring resistance to chipping during automated packaging and transport.

---

Capsule Dosage Forms: Hard Gelatin vs. Softgels

Capsules enclose dry powders, granules, pellets, or non-aqueous liquids within a soluble gelatin or polymeric shell.

Capsules:
  |-- Hard Gelatin / HPMC Capsules
  |     |-- Two-piece (Body + Cap)
  |     |-- Moisture content: Gelatin (13-16%), HPMC (4-6% for moisture-sensitive APIs)
  |     |-- Standard Sizes: 000 (largest, ~1.37 mL) to 5 (smallest, ~0.13 mL)
  |-- Soft Gelatin Capsules (Softgels)
        |-- One-piece, hermetically sealed
        |-- High plasticizer content (Glycerin, Sorbitol) yielding flexible shell
        |-- Fill: Non-aqueous lipophilic liquids, PEG solutions, self-emulsifying oils
        |-- Incompatibilities: > 5% water fills, low MW aldehydes (gelatin cross-linking)

---

Modified-Release Technologies and Formulations

Modified-release dosage forms alter the timing, rate, or anatomical site of drug release to optimize therapeutic efficacy, reduce dosing frequency, and minimize adverse events.

Enteric Coating (Delayed-Release)

Enteric coatings protect acid-labile drugs from gastric degradation (e.g., proton pump inhibitors like omeprazole) or protect the gastric mucosa from irritating drugs (e.g., enteric-coated aspirin).

• Mechanism: Enteric polymers contain free carboxylic acid side chains that remain un-ionized and water-insoluble at acidic gastric pH ($1.0\text{ to }3.0$). When the dosage form empties into the duodenum and jejunum ($\text{pH} > 5.5\text{ to }6.8$), the carboxyl groups ionize into soluble carboxylate salts, triggering rapid polymer dissolution.
• Key Polymers: Cellulose acetate phthalate (CAP), Hydroxypropyl methylcellulose phthalate (HPMCP), Methacrylic acid-ethyl acrylate copolymers (Eudragit L dissolves at $\text{pH} \ge 5.5$; Eudragit S dissolves at $\text{pH} \ge 7.0$).

Extended-Release (ER) Mechanisms

1. Hydrophilic Swellable Matrix: The API is uniformly blended with a high-molecular-weight hydrophilic polymer such as hydroxypropyl methylcellulose (HPMC / Hypromellose). Upon contact with gastrointestinal fluid, the surface polymer hydrates to form a viscous, rubbery gel layer. Drug molecules release via a combination of diffusion through the gel layer and gradual polymer erosion.
2. Insoluble / Lipid Matrix: The API is embedded in a rigid, non-swellable matrix of ethylcellulose, carnauba wax, or polyvinyl acetate. Gastrointestinal fluids penetrate the tortuous pores of the matrix to dissolve the drug, which leaches out by passive diffusion. The insoluble porous matrix shell remains intact and is excreted in the feces.
3. Osmotic-Controlled Release Oral Delivery Systems (OROS):
   • Architecture: A rigid tablet core containing the API and an osmotic driving agent (e.g., sodium chloride) is encapsulated by a water-permeable, drug-impermeable semipermeable cellulose acetate membrane. A precision laser-drilled orifice penetrates the membrane.
   • Mechanism: Water from the GI tract enters the core osmotically across the semipermeable membrane, generating hydrostatic pressure that pumps the drug solution or suspension out through the laser-drilled orifice at a constant zero-order rate ($dM/dt = \text{constant}$).
   • Clinical Advantage: Drug delivery rate is independent of gastrointestinal pH, motility, enzymatic activity, and fed or fasted state (e.g., nifedipine extended-release / Adalat XL, methylphenidate / Concerta).
   • Patient Counseling: Patients must be reassured that the non-absorbable polymer shell ("ghost tablet") will appear intact in their stool after complete drug delivery.

Critical Safety Considerations: Dose Dumping and Manipulation

• Dose Dumping: A sudden, premature release of the entire drug payload from a modified-release formulation, resulting in toxic peak plasma concentrations. This can occur when modified-release opioids or antihypertensives are crushed, chewed, or co-ingested with ethanol, which dissolves the rate-controlling polymer barrier.
• Do Not Crush Guidelines: Pharmacists must consult authoritative references (e.g., ISMP and Health Canada "Do Not Crush" lists) to prevent inadvertent crushing of extended-release or enteric-coated medications for administration via enteral feeding tubes.